The purpose of this study is to compare a usual treatment alone to using Durvalumab plus the usual treatment. Learn more about the EA8192 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
EA8192
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
